BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Mating injuries may lead scientists to identify dinosaurs’ sex- Viable Tips for Seniors to Purchase a Minimal expense Jeep Wrangler
- Monetary Wellness: Planning Tips for Independence from the rat race
- Top Music and Dance Celebration: Which One Gets You Going?
- Audits of Espresso Types: Which Brew Is for You?
- Improving as a Pioneer: Examples from My Vocation
- Manual for Vegetarian Protein Powder
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Taco Bell debuts its Baja Blast pie, and the reactions may surprise you
